Oncothyreon Inc (ONTY) was a big mover last session, as the company saw its shares surge nearly 16% on the day. Shares rallied after the company presented positive data on its HER2-positive metastatic breast cancer treatment candidate ONT-380 at this year's annual American Society of Clinical Oncology conference in Chicago. ONT-380 was found successful in reducing tumors in patients who no longer responded to other treatments. The news led to far more shares changing hands than in a normal session resulting in solid volume. This continues the recent uptrend for the company as the stock is now up 165.4% in the past one-month time frame.
The company has seen one positive revision in the past one month, while its Zacks Consensus Estimate hasn’t been in trend over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Oncothyreon currently carries a Zacks Rank #2 (Buy), while its Earnings ESP is positive.
Another favorably placed stock in the biomedical industry is Actelion Ltd. (ALIOF), sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment